17 recruiting, 12 terminated, 8 completed, 4 withdrawn. 29 Phase 2, 21 Phase 1, 3 Phase 3, 1 Early Phase 1.
Follow Pacritinib: new trials by email Literature Review of Pacritinib trials Research Report on Pacritinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-10-27 | 2026-10-22 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2026-09-29 | 2026-10-14 |
| Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors Pacritinib - Prostate Cancer | Phase 2 | Recruiting | Medical College of Wisconsin | 32 | 2026-09-03 | 2026-09-09 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Not yet recruiting | John Mascarenhas | 26 | 2026-05-04 | 2026-03-18 |
| Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia Pacritinib - Myelofibrosis，MF | Phase 2 | Recruiting | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | 30 | 2026-04-15 | 2026-10-02 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia Pacritinib, Hydroxyurea - Leukemia, Myelomonocytic, Chronic | Phase 2 | Recruiting | Theradex | 66 | 2026-01-01 | 2026-08-18 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined Tagraxofusp, Pacritinib - Myelofibrosis，MF | Early Phase 1 | Recruiting | University of Kansas Medical Center | 20 | 2025-08-25 | 2026-05-06 |
| A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) Pacritinib, Placebo - VEXAS, VEXAS Syndrome | Phase 2 | Recruiting | Swedish Orphan Biovitrum | 156 | 2025-05-28 | 2026-10-16 |
| Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) Pacritinib - KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease | Phase 2 | Recruiting | National Cancer Institute (NCI) | 75 | 2025-03-17 | 2026-10-16 |
| Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Pacritinib - E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS | Phase 1 | Recruiting | Washington University School of Medicine | 15 | 2025-02-13 | 2026-07-15 |
| Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma bemcentinib, pacritinib - Advanced Lung Adenocarcinoma | Phase 1 / Phase 2 | Terminated | The University of Texas Health Science Center at San Antonio | 4 | 2024-12-27 | 2026-05-26 |
| Pacritinib in CMML Pacritinib, Azacitidine - Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Douglas Tremblay | 26 | 2024-09-18 | 2026-08-11 |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib - Myelofibrosis, Moderate Thrombocytopenia | Phase 2 | Recruiting | Karyopharm Therapeutics Inc | 58 | 2024-04-22 | 2026-02-12 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Pacritinib - T-Cell Neoplasm, Lymphoproliferative Disorders | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 100 | 2023-03-29 | 2026-01-29 |
| Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Pacritinib - Graft vs Host Disease | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2023-03-06 | 2026-09-28 |
Showing 20 of 46. Sign in to see all of them.
Primary Myelofibrosis (16) · Myeloproliferative Disorders (9) · Myelodysplastic Syndromes (6) · Bone Marrow Diseases (5) · Leukemia, Myelomonocytic, Chronic (5) · Polycythemia Vera (5) · Thrombocythemia, Essential (5) · Anemia (4) · Hematologic Diseases (4) · Leukemia, Myeloid, Acute (4) · Thrombocytopenia (4) · Lymphoproliferative Disorders (3) · Splenomegaly (3) · Graft vs Host Disease (2) · Hemorrhagic Disorders (2)
CTI BioPharma (9) · Washington University School of Medicine (4) · National Cancer Institute (NCI) (3) · University of Michigan Rogel Cancer Center (3) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (2) · Swedish Orphan Biovitrum (2) · University of Washington (2) · Baxalta now part of Shire (1) · Bhavana Bhatnagar (1) · City of Hope Medical Center (1) · Douglas Tremblay (1) · Fox Chase Cancer Center (1) · Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (37) · United Kingdom (7) · France (6) · Germany (6) · Hungary (5) · Italy (5) · Netherlands (5) · Spain (5) · Belgium (4) · Canada (4) · Czechia (4) · Australia (3) · Romania (3) · Russia (3) · South Korea (3)
Deepak Kilari, MD (2) · Najla El Jurdi, M.D. (2) · Ryan Wilcox, MD, PhD (2) · Simran Singh (2) · Abdulraheem Yacoub, Doctor of Medicine (1) · Abdulraheem Yacoub, MD (1) · Anna Halpern (1) · Anna Halpern, MD (1) · Benjamin R Tan, M.D. (1) · Beth Ziemba (1) · Bhavana Bhatnagar, DO (1) · Camille Abboud, M.D. (1) · Chetan Jeurkar, DO (1) · Courtney DiNardo, MD (1) · Daniel Morgensztern, M.D. (1)
PMID 33275766, PMID 34551507, PMID 12473512, PMID 29382747, PMID 30627694, PMID 33232476, PMID 33753457, PMID 36469321, PMID 39400386, PMID 41753113, PMID 42316774
2015 (1), 2025 (1), P01CA108671 (1), P30CA033572 (1), R01CA265929 (1), R01CA269766 (1), R01HL133823 (1), R21CA159265 (1)